Nutraceuticals Composition A (metabolic capacity enhancing compositions) comprises extraction or powder from White Kidney Bean, Green Tea, Green Coffee Bean, Garcinia Cambogia, Gymnema Sylvestre, L-Carnitine, Guarana, Ginger Root, Dandelion Root, Capsicum Cayenne, Licorice Root, Ascorbic Acid, d-Calcium Pantothenate, Pyridoxine HCl, Potassium Chloride, Magnesium Carbonate, and Chromium Yeast. Nutraceuticals Composition B (immunity capacity enhancing compositions) comprises extraction or powder from Grape Seed, Ginseng, Garlic, Rosehips, Green tea (Decaf), Astragalus, Beta Glucan Yeast, Reishi, Shitake, Maitake, Agricus blazei, Turkey Tail, Cordyceps, and Coenzyme CoQ10. The methods to make a synergistic Composition A and Composition B are formulated and are capable to provide a bioavailable dietary supplement and phytonutrients that can help modulate metabolism and enhance the human immune system. The supplementation, consumption, of these nutraceutical formulas have preventive and therapeutic roles for chronic diseases, and thus provide anti-aging effects.

The disclosed compositions methods relate to a dietary supplement for subjects with slow caffeine metabolism and comprises paraxanthine and optionally other compounds that modulate the effects of paraxanthine. Uses for the paraxanthine-containing supplements contain improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite in a slow caffeine metabolizer subject.

This disclosure provides a method of treating an infection or inflammation of an eye of a mammal including contacting an eye with a solution comprising sterilized water and protocatechuic acid. The protocatechuic acid may be between about 0.01 wt % and 1.25 wt % in the solution. The solution may include saline. The solution may include ciprofloxacin and/or norfloxacin. This disclosure further provides a method of disinfecting a contact lens including contacting a contact lens with a solution including protocatechuic acid. The solution may include a surfactant. The surfactant may include polyethylene glycol esters of fatty acids, coconut, polysorbate, polyoxyethylene or polyoxypropylene ethers of high alkanes C12-C18. The surfactant may include poly(oxypropylene)-poly(oxyethylene) adducts of ethylene diamine having a molecular weight about 7,500 to about 27,000 wherein at least about 40 weight percent of the adducts is poly(oxyethylene).

This disclosure provides a method of treating an infection or inflammation of an eye of a mammal including contacting an eye with a solution comprising sterilized water and protocatechuic acid. The protocatechuic acid may be between about 0.01 wt % and 1.25 wt % in the solution. The solution may include saline. The solution may include ciprofloxacin and/or norfloxacin. This disclosure further provides a method of disinfecting a contact lens including contacting a contact lens with a solution including protocatechuic acid. The solution may include a surfactant. The surfactant may include polyethylene glycol esters of fatty acids, coconut, polysorbate, polyoxyethylene or polyoxypropylene ethers of high alkanes C12-C18. The surfactant may include poly(oxypropylene)-poly(oxyethylene) adducts of ethylene diamine having a molecular weight about 7,500 to about 27,000 wherein at least about 40 weight percent of the adducts is poly(oxyethylene).

A cosmetic composition for alleviating skin barrier dysfunction, a pharmaceutical composition for preventing or treating skin barrier dysfunction, a quasi-drug composition for preventing or alleviating skin barrier dysfunction, a method for alleviating skin barrier dysfunction, and a method for preventing or treating skin barrier dysfunction. Hydroxycinnamic acid, isoamyl acetate, or betaine promotes autophagic activity independently of the mTOR pathway in keratinocytes and accelerates the turnover of the epidermis to increase the thickness of the epidermis, thereby improving the barrier function and preventing the senescence-induced attenuation of the epidermis.

A cosmetic composition for alleviating skin barrier dysfunction, a pharmaceutical composition for preventing or treating skin barrier dysfunction, a quasi-drug composition for preventing or alleviating skin barrier dysfunction, a method for alleviating skin barrier dysfunction, and a method for preventing or treating skin barrier dysfunction. Hydroxycinnamic acid, isoamyl acetate, or betaine promotes autophagic activity independently of the mTOR pathway in keratinocytes and accelerates the turnover of the epidermis to increase the thickness of the epidermis, thereby improving the barrier function and preventing the senescence-induced attenuation of the epidermis.

A cosmetic composition for alleviating skin barrier dysfunction, a pharmaceutical composition for preventing or treating skin barrier dysfunction, a quasi-drug composition for preventing or alleviating skin barrier dysfunction, a method for alleviating skin barrier dysfunction, and a method for preventing or treating skin barrier dysfunction. Hydroxycinnamic acid, isoamyl acetate, or betaine promotes autophagic activity independently of the mTOR pathway in keratinocytes and accelerates the turnover of the epidermis to increase the thickness of the epidermis, thereby improving the barrier function and preventing the senescence-induced attenuation of the epidermis.

Methods and uses of compositions (e.g. comprising one or more microbial strains, one or more components, one or more metabolites, or a combination thereof) for treating neurodegenerative diseases, disorders, and conditions are disclosed.

Methods and uses of compositions (e.g. comprising one or more microbial strains, one or more components, one or more metabolites, or a combination thereof) for treating neurodegenerative diseases, disorders, and conditions are disclosed.

The present invention relates to a crystalline form of compound 3-((L-valyl)amino)-3,3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof.